This is Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent ormetastatic PD-L1+ head and neck squamous cell carcinoma.
A phase 3 randomized, open-label study to evaluate the efficacy and
safety of petosemtamab plus pembrolizumab vs pembrolizumab in
first-line treatment of recurrent or metastatic PD-L1+ head and neck
squamous cell carcinoma.
